ArticleJournal of mass spectrometry : JMS2026
Characterisation of Antisense Oligonucleotides by Ion-Pair Reversed-Phase UHPLC-HRMS: Method development using Design of Experiments.
Article in Journal of mass spectrometry : JMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The quality control of therapeutic antisense oligonucleotides (ASOs) poses significant analytical challenges due to the complexity of their synthesis and degradation processes and the need to ensure the safety and efficacy of active pharmaceutical ingredients (APIs). In this study, an ion-pair reversed-phase ultra-high-performance liquid chromatography-high-resolution mass spectrometry (IP-RP-UHPLC-HRMS) method based on Orbitrap technology was developed using fomivirsen (FMV) and tofersen (TFR) as model compounds. A preliminary scouting phase was dedicated to selecting the type of ion-pair reagent and MS parameters settings (sheath gas, auxiliary gas temperature and S-lens), based on MS spectrum quality (charge state distribution, presence of adducts and in-source fragments), MS signal height and chromatographic peak shape. Design of Experiments (DoE) through response surface methodology was employed to evaluate the effects of the following factors in depth: concentration of the ion pair reagent N,N-diisopropylethylamine and of 1,1,1,3,3,3-hexafluoroisopropanol in the mobile phase and elution gradient slope. The responses selected were the UV height and baseline width of the main peak of the APIs, as well as the resolutions between selected impurities from their extracted MS chromatograms. A multidimensional space (sweet spot) was defined in which the response requirements were met, enabling multicriteria optimisation and the set-up of two distinct IP-RP-UHPLC-MS methods for FMV and TFR characterisation, based on shared mobile phase components and MS parameters. All four FMV impurities and 13 out of 15 detected TFR impurities were identified above 0.1%. DoE approach has been demonstrated to be an effective tool for achieving a balance between sensitivity and selectivity in the analysis of ASOs, identifying optimum conditions tailored to oligonucleotide type and ion-pair agent and paving the way for more structured development processes, as recommended by recent regulatory requirements for pharmaceutical analytical procedure development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.